A phase Ⅱ trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma
- VernacularTitle:多西他赛联合奈达铂、氟尿嘧啶治疗晚期食管癌的临床观察
- Author:
Guo JING-FENG
1
;
Zhang BO
;
Wu FENG
;
Wang BING
;
Xing HUI
;
Zhu GUAN-YU
;
Nie XIANG-YANG
;
Peng JING
Author Information
1. 广州市番禺区何贤纪念医院
- Keywords:
Esophageal neoplasm;
chemotherapy;
nedaplatin;
docetaxel;
5-fluorouracil
- From:Chinese Journal of Cancer
2010;29(3):348-352
- CountryChina
- Language:Chinese
-
Abstract:
Background and Objective:Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma.This study was to evaluate the efficacy and toxicity of docetaxeI plus nedaptatin and 5-fluorouracil (DNF regimen)in treating advanced esophageal carcinoma.Methods:Fortythree patients with pathologically confirmed advanced esophageal carcinoma treated by DNF regimen:intravenous infusion of docetaxel(75 mg/m~2)over 1 h,intravenous infusion of nedaplatin(1 00 mg/m~2)over 3 h,intravenous infusion of leucovorin(CF,200 mg/m~2)over 2 h,intravenous injection of 5fluorouracil(375 mg/m~2)over 10 min,followed by a 46-hour infusion of 5fluorouracil(2.6 g/m~2).The cycle was repeated every three weeks.Treatment efficacy was evaluated every two weeks according to the WHO standards.All patients received at least two cycles of chemotherapy.Results:Patients received a total of 144 cycles of treatment,and all were evaluable for efficacy and toxicity.Of the 43 patients,2(4.65%)achieved complete response(CR),25(58.14%)achieved partial response(PR),9 (20.93%)had stable disease(SD),and 7(16.28%)had progressive disease(PD).The overall response rate was 62.8%.The median time-toprogression(TTP)was 201 days and the median survival time(MST)was 310 days.Grade Ⅲ/Ⅳ adverse events mainly included neutropenia (20.93%),febrile neutropenia(4.65%),thrombocytopenia(6.98%)and vomiting(9.30%).One patient died of grade Ⅳ thrombocytopenia.Conclusion:DNF regimen is effective for and well tolerated by patients with advanced esophageal carcinoma.
